Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
57.88
-0.35 (-0.60%)
At close: Nov 20, 2024, 4:00 PM
57.80
-0.08 (-0.14%)
Pre-market: Nov 21, 2024, 5:10 AM EST
BMY Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2023. The number of employees decreased by 200 or -0.58% compared to the previous year.
Employees
34,100
Change (1Y)
-200
Growth (1Y)
-0.58%
Revenue / Employee
$1,391,056
Profits / Employee
-$212,845
Market Cap
117.39B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34,100 | -200 | -0.58% |
Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
Dec 31, 2020 | 30,250 | 250 | 0.83% |
Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
Dec 31, 2018 | 23,300 | -400 | -1.69% |
Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
Dec 31, 2016 | 25,000 | 0 | - |
Dec 31, 2015 | 25,000 | 0 | - |
Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
Dec 31, 2013 | 28,000 | 0 | - |
Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
Dec 31, 2011 | 27,000 | 0 | - |
Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
Dec 31, 2006 | 43,000 | 0 | - |
Dec 31, 2005 | 43,000 | 0 | - |
Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
Dec 31, 2003 | 44,000 | 0 | - |
Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
Dec 31, 1999 | 54,500 | -200 | -0.37% |
Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
Dec 31, 1993 | 49,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Sanofi | 86,088 |
The Cigna Group | 72,500 |
Boston Scientific | 48,000 |
Amgen | 26,700 |
Stryker | 26,700 |
BMY News
- 1 day ago - Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 2 days ago - Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms - Business Wire
- 2 days ago - Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - Benzinga
- 3 days ago - Bristol-Myers Squibb: Buy This Bargain Before It's Gone - Seeking Alpha
- 5 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - Business Wire
- 6 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors - Business Wire
- 6 days ago - Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug - Reuters
- 8 days ago - Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock - Benzinga